Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

CytoDel

CytoDel
2012 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Angel LATEST DEAL TYPE
$3.9M LATEST DEAL AMOUNT
3 INVESTORS
Description

Provider of a biotechnology platform intended to produce recombinant derivatives of botulinum neurotoxin. The company's biotechnology platform manipulates the BONT molecule into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons with important implications, enabling medical researchers to develop drugs and facilitate the treatment of nervous system disorders, chronic pain and neuro-degenerative diseases.

Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 423 West 127th Street
  • New York, NY
  • United States

+1 (646) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore CytoDel’s full profile, request a free trial.

CytoDel Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Angel (individual) 16-Jan-2018 $3.9M 00.00 Completed Startup
3. Grant 01-Jul-2017 000.00 Completed Startup
2. Grant 01-Jan-2014 $224K Completed Startup
1. Accelerator/Incubator 13-Dec-2013 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

CytoDel Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Amgen Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
000 00000 Corporation Indianapolis, IN 00000 000000 - 000
0000 000000 Corporation Frankfurt, Germany 0000
00000000 Corporate Backed or Acquired Dublin, Ireland 0000 000000&0
To view this company’s complete list of competitors, request access »

CytoDel Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
NYU Innovation Venture Fund Venture Capital Minority 000 0000 000000 0

CytoDel Executive Team (3)

Name Title Board
Seat
Contact
Info
Konstantin Ichtchenko Ph.D Chief Strategy Officer, Co-Founder & Co-Inventor
Edwin Vazquez Cintron Ph.D Co-Founder & Director of Research
Philip Band Ph.D Co-Founder, Co-Inventor, Chief Executive Officer & Board Member

CytoDel Board Members (1)

Name Representing Role Since Contact
Info
Philip Band Ph.D CytoDel Co-Founder, Co-Inventor, Chief Executive Officer & Board Member 000 0000